by The global acute dystonia market is a fast-growing therapeutic domain owing to the rising incidence of acute dystonia attacks and growing usage of injectable and oral neuromuscular relaxants. Acute dystonia refers to involuntary muscle contractions and awkward postures affecting neck, back, legs, and eyes. It is commonly associated with antipsychotic drugs and treatment includes administering anticholinergic medications.
The global acute dystonia market was valued US$ 120.7 Mn in 2023 and is expected to reach US$ 155.0 Mn by 2031 growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.
Global Acute Dystonia Market Trends require fast relief from painful symptoms for patients. Drugs used for managing acute dystonia include benztropine, trihexyphenidyl, and benzatropine which work by blocking acetylcholine activity in the brain. These anticholinergic medications provide relief within 30 minutes by relaxing cramped muscles. In severe cases of generalized dystonia involving the back and limbs, intravenous anticholinergics and muscle relaxants like baclofen are administered. The growing psychotropic drug usage and rising geriatric population prone to adverse drug reactions is fueling the demand for acute dystonia treatments.
Key Takeaways
Key players operating in the global acute dystonia market are Fresenius Kabi, Amar Healthcare, Johnson & Johnson, PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
The rising prevalence of neurological disorders is driving the growth of the acute dystonia market. According to WHO, over 450 million people currently suffer from neurological disorders globally. This increasing disease burden is raising the demand for treatment therapies like neuromuscular relaxants for acute dystonia
Geographically, North America dominates the global acute dystonia therapeutics market owing to the increasing healthcare expenditure and rising affordability for expensive specialty drugs in the region. However, Asia Pacific region is expected to exhibit the fastest growth during the forecast period owing to the improving access to healthcare in emerging nations.
Market Key Trends
The global acute dystonia market is witnessing a rising trend of increasing collaborative partnerships between drug manufactures and neurological disease associations. For instance, in 2021, Fresenius Kabi conducted a partnership with Dystonia Europe to increase awareness about acute dystonia treatment options. The key focus is on growing education and symposium programs for healthcare professionals and patients.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low as establishing resources, manufacturing facilities, R&D infrastructure and brand recognition in the acute dystonia market requires significant investment of capital which new players usually lack.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are a few established companies that dominate the acute dystonia market. However, availability of generic drugs increases buyer bargaining power to some extent.
Bargaining power of suppliers: The bargaining power of suppliers is moderate since raw material suppliers have established relationships with major players in the acute dystonia market. Switching costs are relatively low.
Threat of new substitutes: The threat of new substitutes is low as there are limited treatment alternatives available for acute dystonia.
Competitive rivalry: The competition in the acute dystonia market is high owing to the presence of numerous international and local players. Key players focus on new product launches and geographical expansion to gain market share.
North America accounts for the largest share of the Global Acute Dystonia Market Regional Analysis primarily due to the presence of major players, increasing awareness, high healthcare expenditure and rising prevalence of dystonia in the region. Asia Pacific is expected to witness the fastest growth in the acute dystonia market during the forecast period attributed to rapidly improving healthcare infrastructure, growing medical tourism industry, rising healthcare expenditure and increasing patient population.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
